Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

China Has Big Presence in Top 10 Biotech IPOs in 2019

New rules went into effect during 2018 on the Hong Kong stock exchange allowing companies that did not have a product on the market or generate revenue to list on the exchange.

Read More »

Despite IPO Rumors, BioNTech Closes Upsized Series B Worth $325 Million

Mainz, Germany-based BioNTech – which was recently believed to be maneuvering for an initial public offering – instead raised $325 million in a Series B financing round, one of the largest single private funding rounds for a biotechnology company in European history.

Read More »

Four Investors Indicted on Federal Fraud Charges Involving Vermont Biotech Company

A federal grand jury recently filed criminal charges against several developers for fraud involving a Vermont biotech company.

Read More »

From Isolation to Anticipation: How technology continues to improve the lives of rare disease families

Working in the rare disease space has never been more rewarding than it is today. Technology is turning what was once thought to be impossible into actual, tangible realities for physicians, patients, and families. There are many exciting advancements happening now – in real time – and even more on the horizon that demand our attention and advocacy to help bring them to light.

Read More »

Bayer teams up with biotech firm Arvinas in deal worth up to $750 million

German drugmaker Bayer signed an alliance with Arvinas Inc. to gain access to the U.S. biotech firm’s experimental protein drugs and crop protection technology in a deal worth up to $750 million.

Read More »

Four Biotech Companies List on the Nasdaq Today

Four biotech companies began trading on the Nasdaq this morning.

Read More »

Pfizer Acquires Rare-Drug Company Therachon for $810 Million

Pfizer announced plans to buy Therachon, a rare disease biotech company based in Basel, Switzerland.

Read More »

Gilead and Goldfinch Bio Form Strategic Collaboration

Gilead Sciences Inc. and Goldfinch Bio Inc. announced a strategic collaboration to discover, develop and commercialize a pipeline of innovative therapeutics for diabetic kidney disease (DKD) and certain orphan kidney diseases.

Read More »

Alphabet’s GV leads funding in gene editing company Verve Therapeutics

Alphabet’s venture capital arm GV led a $58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases.

Read More »

FDA approves expanded label for Praluent

The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals’ cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom